1JPM-Conference-Presentation-FINAL5 ADC.pdf

《1JPM-Conference-Presentation-FINAL5 ADC.pdf》由会员分享，可在线阅读，更多相关《1JPM-Conference-Presentation-FINAL5 ADC.pdf（22页珍藏版）》请在三个皮匠报告上搜索。

1、Ameet Mallik,CEOJanuary 11,2023J.P.Morgan Healthcare Conference2Forward-Looking StatementsThis presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA(ADC Therapeutics“,“we”or“us”)for informational purposes only and not for any other purpose.Nothing contained in

2、 this presentation is,or should be construed as,a recommendation,promise or representation by the presenter or ADC Therapeutics or any officer,director,employee,agent or advisor of ADC Therapeutics.This presentation does not purport to be all-inclusive or to contain all of the information you may de

3、sire.Information provided in this presentation and any accompanying oral presentation speak only as of the date hereof.This presentation contains statements that constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of

4、1995.Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.Factors that may cause such differences include,but are not limited to:the Companys ability to continue to commercialize ZYNLONTA in the United State

5、s and future revenue from the same;Swedish Orphan Biovitrum AB(Sobi)ability to successfully commercialize ZYNLONTA in the European Economic Area and market acceptance,adequate reimbursement coverage,and future revenue from the same;our strategic partners,including Mitsubishi Tanabe Pharma Corporatio

6、n and Overland Pharmaceuticals,ability to obtain regulatory approval for ZYNLONTA in foreign jurisdictions,and the timing and amount of future revenue and payments to us from such partnerships;the Companys ability to market its products in compliance with applicable laws and regulations;the timing a